



STUDIES OF 4-FURANONE AND 4-OXAZOLONE SUBSTITUTED COUMARINS: SYNTHESIS, PHYSIOLOGICAL AND BIOLOGICAL ACTIVITY

Jitendra B. Patil

Organic Research Laboratory, S S & L S Patkar Varde College, Goregaon(W), Mumbai-400062.

Abstract :

3-(coumarin-4-yl)-5-(substituted benzoyl)-2-(3H)-furanones have been prepared from 3-(substituted benzoyl propionic acid and coumarin-4-aldehyde and characterized on the basis of IR, ¹H NMR and mass spectrometric data. Some of the compounds have been tested for antibacterial activity.

Introduction:

The chemistry of butenolides has attracted more attention in the last few decades due to their novel biological actions used as an important anthelmintic and ascaricidal agents.^{1,2} The butenolide ring present in cardenolides shows a strong oral cardiotonic activity.³ The 3,3-diethylbutylrolactone has been reported to have anticonvulsant activity.⁴ While the butenolides have exhibited antibiotic activity,⁵ anti-inflammatory, analgesic, antitumor, antiviral and anticancer properties also,^{6,7} and potential pharmaceutical interest.^{8,9}

In the present investigations, we report the synthesis and reaction of 3-(coumarin-4-yl)-5-(substituted benzoyl)-2-(3H)-furanones following the literature procedure,¹⁰ with appropriate modification, and a study of biological activity of the resulting products. These compounds

were synthesized according to **Scheme I**. Similarly, 3-(coumarin-4-yl)-5-(substituted benzoyl)-2-(3H)-Oxazolones,^{11,12} In our earlier work, we have assigned E-configuration based on NOE experiments.¹³ These compounds were synthesized according to **Scheme II**.

Results and Discussion:

In our earlier work, we have assigned E-configuration based on NOE experiments.¹³ Similarly, 3-(coumarin-4-yl)-5-(substituted benzoyl)-2-(3H)-Oxazolones, were synthesized from (un)substituted benzoyl glycine by reacting with coumarin-4-aldehyde in the presence of Sodium acetate in acetic anhydride (Scheme II). The structures assigned to the compounds were supported by the results of I.R, ¹H NMR and Mass. Physiological studies: The synthesized molecules of Furanones(20-32) showed λ_{max} between 330nm to 420nm, while the synthesized molecules of Oxazolones(41-59) showed λ_{max} between 330nm to 420nm.

EXPERIMENTAL (General procedure): 4-[(7-propanoyloxy-2H-1-benzopyran-2-one-4-yl)methylene-2-phenyl-(4H)furanone **20**: 7-propanoyloxycoumarin-4-carboxaldehyde,**9** (1.23g, 0.005 moles), fused sodium acetate (2.0gm) and benzoyl propionic acid, **17** (0.98g, 0.0055moles) were intimately mixed by grinding in mortal. The mixture was mixed with acetic anhydride(3ml), heated on a boiling water bath for 20min., with shaking and stirring, diluted from ethanol solvent afforded 20; yield 0.95g(49%); mp 260-262°C. IR(KBr):3152, 839, 1767, , 1620, 1506, 1251, 1221, 1135, 1006, 757 cm⁻¹; ¹H-NMR(CDCl₃): δ = 1.30(3H, t, *J* = 7.61Hz), 2.64-2.71(m, 2H), 6.62(s, 1H), 6.73(s, 1H), 7.09(1H, d, *J* = 2.3Hz), 7.13(1H, d, *J* = 2.3Hz), 7.19(1H, d, *J* = 2.3Hz), 7.28(2H, d, *J* = 8.2 Hz,), 7.42(s, 1H), 7.67(2H, d, *J* = 8.2Hz), 7.73(1H, d, *J* = 8.6Hz); MS: *m/z* (M⁺,389).

4-[(7-propanoyloxy-2H-1-benzopyran-2-one-4-yl)methylene-2-(4-methoxyphenyl)-5(4H)furanone **21**; yield 1.19g (57%); mp 256-258°C. IR(KBr): 3163, 3035, 2868, 1783, 1561, 1349, 1281, 755 cm⁻¹; ¹H-NMR(CDCl₃): δ = 1.29(3H, t, *J* = 7.52Hz), 2.61-2.69 (m, 2H), 3.89(s, 3H), 6.68(s, 1H), 7.00 (1H, d, *J* = 9.2Hz), 7.12(1H, d, *J* = 2.2Hz), 7.14(1H, d, *J* = 2.2Hz), 7.23(2H, d, *J* = 2.2Hz), 7.39(s, 1H), 7.73-7.77(s, 3H); MS: *m/z* (M⁺, 419).

4-[(7-butanoyloxy-2H-1-benzopyran-2-one-4-yl)methylene-2-phenyl-5(4H)furanone **22**; yield 0.95g (61%); mp 260-262°C. IR(KBr): m.p.=270-272°C char. IR(KBr):3155, 927, 2878, 1750, 619, 1574, 1506, 1214, 1133, 990, 856, 753 cm⁻¹; ¹H-NMR (CDCl₃): δ = 0.98(3H, t, *J* = 7.4Hz), 1.49-1.75 (m, 2H), 2.52 (2H, t, *J* = 6.9Hz), 6.54(s, 1H), 6.66(s, 1H), 7.01-7.23(m, 5H), 7.34(s, 1H), 7.59 (2H, d, *J* = 8.6Hz), 7.63(s, 1H).

4-[(7-butanoyloxy-2H-1-benzopyran-2-one-4-yl)methylene-2-(4-methyl)phenyl-5(4H)furanone **23**; The compound was obtained as orange yellow

needle from ethanol, 1.19g (yield=57%, m.p.=265-268°C char). IR(KBr): 3163, 3035, 1783, 1699, 1561, 1349, 1281, 988, 750 cm⁻¹; ¹H-NMR(CDCl₃): δ=1.07(3H, t, J = 7.4Hz), 1.76-1.87(m, 2H), 2.43

(s, 3H), 2.60(2H, t, J = 7.4Hz), 6.61(s, 1H), 6.68(s, 1H), 6.73(s, 1H), 7.08(1H, d, J = 2.3Hz), 7.12 (1H, d, J= 2.0 Hz), 7.27 (1H, t, J = 6.2Hz), 7.42(s, 1H), 7.65-7.75(m, 3H). 4-[(7-butanoyloxy-2H-1-benzopyran-2-one-4-yl)methylene-2-(4-methoxyphenyl)-5(4H) furanone **24**; yield 1.27g (59%); mp 260-262°C. IR(KBr): 3159, 2997, 2841, 1778, 1705, 1607, 1504, 1233, 989, 828 cm⁻¹; ¹H-NMR(CDCl₃): δ=1.07(3H, t, J = 7.5Hz), 1.78-1.84(m, 2H), 2.60(2H, t, J = 7.8Hz), 3.90(s, 3H), 6.67(2H, d, J=2.3Hz), 7.12(2H, d, J = 2.3Hz), 7.13(2H, t, J=2.3 Hz), 7.20(1H, d, J = 2.3Hz), 7.39(s, 1H), 7.74-7.77(m, 2H). 4-[(7-benzyloxy-2H-1-benzopyran-2-one-4-yl)methylene-2(4-methyl)phenyl-5(4H) .

furanone **25**, yield 1.52g (61%); mp284-286°C. IR(KBr): 3161, 3030, 2917, 1785, 1474, 1413, 1347, 1260, 1134, 1025, 990 & 752 cm⁻¹; ¹H-NMR(CDCl₃): δ=2.57(s, 3H), 6.65 (s, 1H), 6.77(s, 1H), 7.20-7.47(m, 4H), 7.49(s, 1H), 7.55(2H, t, J = 7.5Hz), 7.69(2H, t, J = 7.3Hz), 7.81 (2H, d, J = 8.8Hz), 8.22(2H, d, J = 7.0Hz). 4-[(7-benzyloxy-2H-1-benzopyran-2-one-4-yl)methylene-2(4-methoxy)phenyl-5(4H)

furanone **26**; yield 1.23g (53%); mp284-286°C. IR(KBr): 3161, 3030, 2917, 1785, 1474, 1413, 1347, 1260, 1134, 1025, 990 & 752 cm⁻¹; ¹H-NMR(CDCl₃) δ: 3.90(s, 3H), 6.70 (s, 1H), 6.91-7.20 (m, 3H), 7.29(s, 1H), 7.32 (1H, t, J = 6.6Hz), 7.35(1H, t, J = 7.3Hz), 7.53-7.81 (m, 6H), 8.22 (2H, d, J = 7.3Hz); MS: mz(M⁺, 467).

4-[(7-(2-chlorobenzoyloxy -2H-1- benzopyran -2-one -4-yl)methylene-2(4-methyl) phenyl-5(4H)furanone **27**, yield 1.52g (59%); mp258-260°C. IR(KBr): 3161, 3030, 2917, 1785, 1474, 1413, 1347, 1260, 1134, 1025, 990, 752 cm⁻¹; ¹H-NMR(D₂SO₄) δ 2.59(s, 3H), 6.93(s, 1H), 7.24(s, 2H), 7.44-7.71(m, 6H), 7.87(1H, d, J = 8.8Hz), 8.07(2H, d, J = 7.0Hz), 8.24(s, 1H), 8.42(1H, d, J = 7.0Hz). 4-[(7-Benzyl-2H-1-benzopyran-2-one-4-yl)methylene-2(4-methyl)phenyl-5(4H)

Furanone **28**; yield 1.42g (53%); mp245-247°C. IR(KBr): 3160, 2997, 2841, 1778, 1705, 1607, 1504, 1351, 1251, 1142, 829 cm⁻¹; ¹H-

NMR(CDCl₃): 82.44(s, 3H), 5.17(s, 2H), 6.62(s, 1H), 6.96(2H, d, J = 2.45Hz), 7.00(1H, d, J = 2.5Hz), 7.30(1H, d, J = 8.3Hz), 7.37(s, 1H), 7.38-7.64(m, 6H), 7.67(3H, d, J = 6.4Hz).

4-[(7- Benzyl -2H-1- benzopyran -2-one -4-yl)methylene -2(4-methoxy)phenyl-5(4H) furanone **29**; yield 1.40g (62%); mp284-286°C. IR(KBr): 3160, 2841, 1778, 1705, 1607, 1504, 1351, 1251, 989, 829 cm⁻¹; ¹H-NMR(CDCl₃): δ 3.89(s, 3H), 5.16(s, 2H), 6.50(s, 1H), 6.68(s, 1H), 6.95-7.12(m, 4H), 7.26-7.44(m, 6H), 7.64(s, 1H), 7.67(s, 1H), 7.75(s, 1H). 4-[(7-(2'-Chlorobenzyl-2H-1-benzopyran-2-one-4-yl)methylene-2-phenyl)-5(4H)

furanone **30**; yield 1.20g (53%); mp215-218°C. IR(KBr): 3146, 1784, 1716, 1610, 1538, 1507, 1352, 1281, 1185, 1160, 1035, 993 and 743 cm⁻¹; ¹H-NMR(CDCl₃): δ= 5.27(s, 2H), 6.51(s, 1H), 6.79(s, 1H), 6.91-7.03(m, 3H), 7.29-7.34(m, 3H), 7.43-7.54(m, 5H), 7.64-7.77(m, 1H), 7.78 (1H, d, J = 3.6Hz), 7.82(1H, d, J = 9.9Hz).

4-[(7-(4-NitroBenzyl)-2H-1-benzopyran-2-one -4-yl)methylene -2(4-methyl)phenyl-5(4H)furanone **31**; yield 1.49g (62%); mp 290-293°C. IR(KBr): 3032, 2856, 1778, 1701, 1611, 1518, 1346, 1281, 1185, 1148, 987 & 827; ¹H-NMR (CDCl₃) :δ=2.66(s, 3H), 5.36(s, 2H), 6.47(s, 1H), 6.78(s, 1H), 6.91-6.96(3H, t, J = 3.6Hz), 7.60(1H, d, J = 2.6Hz), 7.62(3H, d, J = 3.6Hz), 7.75(3H, t, J= 3.6 Hz), 8.25(2H, t, J= 3.6Hz).

4-[(7-(4-Cyano Benzyl -2H-1-benzopyran-2-one -4-yl)methylene -2(4-methyl)phenyl-5(4H)furanone **32**; yield 1.25g (58%); mp284-286°C. (yield=58%, m.p.=250-255°Cchar). IR(KBr): 3436, 3072, 2854, 1728, 1612, 1509, 1352, 1214, 1183, 1019 and 966 cm⁻¹; ¹H-NMR (CDCl₃): δ= 2.43(s, 3H), 5.22 (s, 2H), 6.52(s, 1H), 6.74(s, 1H), 6.92(3H, d, J = 2.6Hz), 7.00(1H, d, J = 2.6Hz), 7.28(s, 1H), 7.43(s, 1H), 7.57(2H, d, J = 8.4Hz), 7.66-7.57(m, 5H).

By successfully study of furanone, we prepared analogues Oxazolones which tremendous application in antitumour and anticancer activity. 4-(7-propanoyloxy-2H-benzopyran-2-one-4-yl)methylene -2-phenyl-5(4H) oxazolone **41**: 7-propanoyloxy benzopyran-2-one-4-carboxaldehyde (1.23g, 0.005moles), fused sodium acetate (2.0gm) and benzoyl propionic acid, **17** (0.98g, 0.0055moles) benzoyl Glycine **38** (0.98g

,0.0055moles) mixed with Ac₂O (3ml), heated on a boiling water bath for 20 min. Cooled and filtered, dried, yield 1.03 g (53%); mp 235-237°C. IR(KBr): 3135, 3064, 2941, 1766, 1619, 1558, 1452, 1355, 1297, 1137, 978 ,769 cm⁻¹; ¹H-NMR(CDCl₃): δ=1.30 (3H, t, J = 7.50Hz), 2.10-2.69(m, 2H), 2.43(s, 3H), 2.60(2H, t, J = 7.4Hz), 7.17(1H, d, J = 2.2Hz), 7.21(1H, d, J = 2.2 Hz), 7.58 (2H, t, J = 7.2 Hz), 7.69-7.84(m, 3H), 8.23(1H, d, J = 7.0 Hz), 8.84(2H, d, J = 6.7Hz). MS: mz (M⁺, 389).

4-((7-propanoyloxy-2-one-4-yl)methylene)-2-(2-chlorophenyl)5(4H) oxazolone **42**: The compound was obtained as yellow needle from ethylacetate, 1.08g(yield=51%,

m.p.=210-220°C). IR(KBr):3135, 2943, 1801, 1760, 1617, 1559, 1474, 1350, 1262, 1132, 977, 866 &733 cm⁻¹; ¹H-NMR(CDCl₃):δ=1.30(3H, t, J = 7.6Hz), 2.60-2.71(m, 2H), 7.58

(2H, d, J = 7.6Hz), 7.21(1H, d, J = 2.2Hz), 7.58(2H, t, J = 2.73Hz), 7.75(s, 1H), 7.82 (1H, d, J = 8.6 Hz), 8.16 (1H, d, J = 7.0Hz). MS: mz (M⁺, 423).

4-(7-Butonoyloxy-2H-bezopyran-2-one-4-yl)methylene)-2-phenyl-5(4H)oxazolone **43**; yield 1.02g (53%); IR(KBr): 3097, 2944, 1780, 1760, 1617, 1558, 1328, 1262, 1137, 902 & 697 cm⁻¹; ¹H-NMR (CDCl₃): δ=1.07(3H , t , J = 7.4Hz), 1.56-1.88 (m, 2H), 2.61 (2H, t, J = 7.22Hz), 7.11-7.20(m, 2H), 7.41(s, 1H), 7.57 (2H, t, J = 7.0Hz), 7.68 (1H, d, J =

7.0Hz), 7.80(2H, d, J = 8.6 Hz), 8.22(2H, d, J =7.02Hz).

4-(7- Butonoyloxy -2H -bezopyran -2- one-4 -yl) methylene)-2-(2-chlorophenyl)-5(4H) oxazolones **44**;yield 1.18g (53%); 190-200°C. IR(KBr): 3083 , 2935, 1803, 1761, 1608, 1559, 1473, 1264, 1179, 974 ,740 cm⁻¹; ¹H-NMR (CDCl₃): δ= 1.30(3H, t, J = 4.5Hz), 1.56-1.88 (m, 2H), 2.60(2H, d, J = 7.6Hz), 7.15(2H, d, J = 7.8Hz), 7.48(s, 2H), 7.84(2H, d, J = 5.5Hz), 7.79(2H, t, J = 7.6Hz), 8.16(1H, d, J = 6.63Hz).

4-((7-benzoyl-2H-bezopyran-2-one-4-yl)methylene)-2-phenyl-5(4H) oxazolone. **45**:

(52%); 1.13g(yield = 52%, m.p.= 240-243 °C char). IR(KBr): 3078, 1870, 1449, 1326, 1248, 1133, 1052, 975, 864 & 769cm⁻¹. ¹H-NMR(CDCl₃):δ=7.36(s,1H), 7.95-8.16(m,7H), 8.21-8.48(m,3H), 8.43-8.48(m, 2H), 8.74(2H, d, J = 7.68Hz).

4-((2-chlorobenzoyl)-2H-bezopyran-2-one-4-yl)methylene)-2-(2-chlorophenyl)-5(4H) oxazolone**46**; yield 1.01g (39%); 190-200°C. IR(KBr): 3078, 1800, 1736, 1558, 1449, 326, 1248, 1132, 1051, 978, 864 & 699 cm⁻¹; ¹H(CDCl₃):δ=7.00(s, 1H), 7.39(s, 2H), 7.427.59(m, 4H), 7.70(1H, t, J = 7.7Hz,), 7.80(2H, t, J = 7.7Hz), 7.99-8.13(m, 3H). 4-[7-(2-Chlorobenzyl)-2H-bezopyran-2-one-4-yl)methylene]-2-phenyl-5(4H) oxazolone **47**; yield 1.12g (49%); mp190-200°C. IR(KBr):3077, 1800, 1710, 1609, 1554, 1450, 1374, 1350, 1280, 1175, 1064, 1064, 1008, 884, 697 cm⁻¹; ¹H-NMR (CDCl₃) : δ= 5.27(s, 2H), 6.95-7.03(m, 2H), 7.23-7.30 (m, 6H), 7.32 (2H, d, J = 3.9Hz), 7.50 (s, 1H), 7.57(s, 1H), 7.61(1H, d, J = 3.5Hz), 7.74(1H, d, J = 8.6Hz).

4-[7-(2-Chlorobenzyl)-2H- bezopyran -2-one-4-yl)methylene]-2-(2-chlorophenyl)-5(4H) oxazolone **48**; yield 1.23g (50%); mp256-258°C. IR(KBr):3080, 1802, 1719, 1617, 1536, 1471, 1430, 1396, 1346, 1209, 1144, 1117, 1033, 1004, 961 &736 cm⁻¹; ¹H-NMR (CDCl₃): δ= 5.27 (s, 2H) , 6.95-7.03(m, 2H), 7.23-7.30(m, 6H), 7.32(2H, d, J = 3.9Hz), 7.50 (s, 1H), 7.57(s, 1H), 7.61 (1H, d, J = 3.5 Hz), 7.74(1H, d, J = 8.6Hz). 4-[7-(4-(nitrobenzy)l-2H-bezopyran-2-one-4-yl)methylene]-2-(2-chlorophenyl)-5(4H) oxazolone **49**; yield 0.98g (38%); 245-248°C. IR(KBr):2923, 2226, 1801, 1714, 1600, 1554, 1452, 1327, 1282, 1145, 1067, 981, 821, 699 & 549 cm⁻¹; ¹H-NMR(CDCl₃): δ= 5.22(s, 2H), 6.92(1H, d, J = 2.34Hz), 6.98 (1H, d, J = 2.7Hz), 7.02(1H, d, J = 2.7Hz), 7.44-7.63(m, 6H), 7.69-7.77(m, 3H), 8.16(1H, d, J = 7.0Hz). 4-[7-(4-cyanobenzyl-2H-bezopyran-2-one-4-yl)methylene]-2-phenyl-5(4H)oxazolone **50**; yield 1.14g (51%); 250-255°C. IR(KBr):2923, 2226, 1801, 1714, 1512, 1452, 1353, 1327, 1282, 1145, 1067, 821549cm⁻¹; ¹H-NMR(CDCl₃):5.22(s, 2H), 6.92(s, 1H), 6.99(1H, d, J = 9.0Hz), 7.24(s, 2H), 7.40 (s, 1H), 7.55-7.77(m, 8H), 8.22(2H, d, J = 7.8Hz). 4-[6-methyl-2H-1-bezopyran-2-one-4-yl] methylene]-2-phenyl-5(4H) oxazolone **51**; yield 0.75g (51%); 253-255°C.IR(KBr):3066, 1801, 1716, 1654 , 620, 1546, 1452, 1346, 1298, 1178, 1066, 759cm⁻¹; ¹H-NMR(CDCl₃):δ= 2.48(s, 3H), 7.30(1H, d, J = 8.6Hz), 7.40(1H ,d, J = 8.6Hz), 7.48(s, 1H), 7.54-7.62(m, 3H), 7.70(1H, t, J = 7.5 Hz), 7.76(s, 1H), 8.23(2H, d,J=7.4 Hz).

4-[6-methyl-2H-1-bezopyran-2-one-4-yl)methylene]-2-(2-Chloro)phenyl-5(4H) oxazolone **52**; yield 0.73g (51%); 268-270°C.IR(KBr):3066, 1801, 1716, 1654, 1620,

1546, 1452, 1346, 1298, 1178, 1066, 883 &759cm⁻¹. ¹H-NMR(CDCl₃):δ=2.48(s,3H),7.30(1H, d, J = 8.2Hz), 7.40(1H, d, J = 8.2Hz), 7.47(1H, d, J = 8.0Hz), 7.54-7.62(m, 4H), 7.76(s, 1H), 8.18(1H, d, J = 8.2Hz).

4-[6-methyl-2H-1-bezopyran-2-one-4-yl)methylene]-2-(2-methyl)phenyl-5(4H) oxazolone **53**;

yield 0.80g (49%); 231-232°C. IR(KBr):3066,2922,1803,1712, 1652,1537, NMR(CDCl₃):δ=2.45(s, 3H),2.82(s, 3H), 7.29(1H, d, J = 8.3Hz), 7.35-7.42 (m,3H), 7.48(s, 1H), 7.54(1H, t, J = 7.3 Hz), 7.61(s, 1H), 7.70(s,1H), 8.15(1H, d, J = 8.3Hz).

4-[7-methyl-2H-1-bezopyran-2-one-4-yl)methylene]-2-phenyl-5(4H) oxazolone

54: yield 0.73g (51%); 268-270°C.

The compound was obtained as orange yellow needles from ethanol,0.56g (yield=34%, m.p.=281-283°C). IR(KBr):3064, 1805, 1714, 1649, 1560, 1537, 1450, 1348, 1174, 952 and 887cm⁻¹. ¹H-NMR(CDCl₃):δ= 2.48(s, 3H), 7.19(1H, d, J = 7.1Hz), 7.21(s, 1H) 7.45(s, 1H), 7.57(2H, t, J = 7.0 Hz), 7.68-7.77(m, 3H), 8.23(2H, d, J = 7.4 Hz).

4-[7-methyl-2H-1-bezopyran-2-one-4-yl)methylene]-2-(2-Chloro)phenyl-5(4H) oxazolone **55:** yield 0.64g (35%); 275-277°C. IR(KBr): 3085, 1805, 1712, , 1618, 1546, 1471, 1344, 1274, 1182, 1043,777 cm⁻¹; ¹H-NMR(CDCl₃): 82.48(s, 3H),7.18(d, J = 7.8Hz, 1H), 7.21(s, 1H), 7.45(1H, t, J = 7.1Hz), 7.51-7.63(m, 3H), 7.70(m, 2H), 8.20 (1H, d, J = 8.3Hz).

4-[7-acetoxy-2H-1-bezopyran-2-one-4-yl)methylene]-2-(2-Chloro)phenyl-5(4H) oxazolone **56:** yield 0.86g (42%); 226-240°C. IR(KBr):3097, 1797, 1701, 1620, 1554, 1537,1350, 1269, 1186, 894 &727 cm⁻¹; ¹H-NMR (CDCl₃): δ=2.32(s, 3H),7.22(1H, d, J = 8.6 Hz), 7.34(s, 1H), 7.56(s, 1H), 7.61(1H, t, J = 8.2

Hz), 7.67(s, 1H), 7.70-7.787(m, 2H),8.13(1H, d, J = 8.6 Hz), 8.22(1H, d, J = 8.6 Hz).

4-[7-acetoxy-2H-1-bezopyran-2-one-4-yl)methylene]-2-(2-methyl)phenyl-5(4H)

oxazolone **57:** yield 0.73g (51%); 268-270°C. 1.07g (yield=55%,m.p.=245-247°C).IR(KBr): 3097, 1805, 1760, 1718, 1604, 1556, 1535, 1348,1265,1178, 1027, m.p.231-232°C, 896 & 736cm⁻¹; ¹H-NMR(DMSO): δ=2.30(s, 3H), 2.66(s, 3H), 7.22(d, J=8.2Hz,1H),7.34(s, 1H), 7.47-7.51(m, 3H), 7.59(s, 1H), 7.63(1H, t, J = 7.7Hz), 8.03(1H, d, J = 8.2Hz), 8.21(1H, d, J = 8.2 Hz).

4-[2H-1-naphth[1,2-b]pyran-2-one-4-yl)methylene]-2-(2-methyl)phenyl-5(4H) oxazolone



58 yield 0.28g (51%); mp263-265°C. IR(KBr):3062, 17971, 1712, 1600, 1552, 1533, 1357, 1271, 1184, 1087, 883 and727cm⁻¹; ¹H-NMR(CDCl₃): δ=2.8(s, 3H), 7.44(2H, d, J = 8.8Hz), 7.58(1H t, J = 7.9Hz), 7.63(s, 1H), 6.68-7.72(m, 2H), 7.84 (1H, d, J = 8.8Hz), 7.76(s, 1H),7.92-7.98(m, 2H), 8.14 (1H, d, J = 8.8Hz), 8.56(1H, t , J = 8.2Hz).

4-[2H-1-naphth[2,3-b]pyran-2-one-4-yl)methylene]-2-(2-methyl)phenyl-5(4H)

oxazolone **59:**yield 0.70g (38%); 268-270°C. IR(KBr):3066, 1797, 1731,1552, 1514, 1131, 1271, 1176, 1271, 1033, 877,723cm⁻¹; ¹H-NMR(CDCl₃):δ=2.78(s, 3H), 7.34-7.42(m, 2H), 7.50-7.54(m, 2H),7.58(2H, t, J = 7.8Hz),7.70(s, 1H),7.92(1H, d, J = 8.3Hz), 7.97(1H, d, J = 8.3Hz), 8.04(1H, d, J = 8.3Hz), 8.14(1H, t, J = 8.3Hz), 8.31(1H, t, J= 8.3Hz).

Antibacterial Screening¹⁴:compounds (**28**, **29**, **31**, **45**, **46**, **47**, **52**, **54** and **58**) have been screened against gram negative *S.aureus* and *E.coli*. using tube dilution technique.

Conclusion:Compounds (**28**, **29**, **31**, **45**, **46**, **47**, **52**, **54** and **58**) were evaluated for their anti microbial activity by Using concentration level of 5μg/ml to 200 μg/ml. The test organism employed were *S.aureus* and *E.coli*.

Scheme I: Synthesis of 4-Furanone substituted Coumarins:**Scheme II: Synthesis of 4-Oxazolone substituted Coumarins:****Table 1-Physiological Studies: Absorption Spectra of Furanones 22-32 and Oxazolone 41-59:**

No.	R and R'	λ_{max}	No.	R and R'	λ_{max}
20	$\text{R} = \text{COCH}_2\text{CH}_3, \text{R}' = \text{H}$	390	44	$\text{R} = \text{COCH}_2\text{CH}_2\text{CH}_3, \text{R}' = \text{Cl}$	390
21	$\text{R} = \text{COCH}_2\text{CH}_3, \text{R}' = \text{OCH}_3$	380	45	$\text{R} = \text{COC}_6\text{H}_5, \text{R}' = \text{H}$	360
22	$\text{R} = \text{COCH}_2\text{CH}_2\text{CH}_3, \text{R}' = \text{H}$	420	46	$\text{R} = \text{COC}_6\text{H}_4\text{Cl}, \text{R}' = \text{Cl}$	370
23	$\text{R} = \text{COCH}_2\text{CH}_2\text{CH}_3, \text{R}' = \text{CH}_3$	395	47	$\text{R} = \text{CH}_2\text{C}_6\text{H}_4\text{Cl}, \text{R}' = \text{H}$	370
24	$\text{R} = \text{COCH}_2\text{CH}_2\text{CH}_3, \text{R}' = \text{OCH}_3$	380	48	$\text{R} = \text{CH}_2\text{C}_6\text{H}_4\text{Cl}, \text{R}' = \text{Cl}$	380
25	$\text{R} = \text{COC}_6\text{H}_5, \text{R}' = \text{CH}_3$	360	49	$\text{R} = \text{CH}_2\text{C}_6\text{H}_4\text{NO}_2, \text{R}' = \text{Cl}$	370
26	$\text{R} = \text{COC}_6\text{H}_5, \text{R}' = \text{OCH}_3$	330	50	$\text{R} = \text{CH}_2\text{C}_6\text{H}_4\text{CN}, \text{R}' = \text{H}$	380
27	$\text{R} = \text{COC}_6\text{H}_4\text{Cl}, \text{R}' = \text{CH}_3$	360	51	$\text{R} = 6-\text{CH}_3, \text{R}' = \text{H}$	380
28	$\text{R} = \text{CH}_2\text{C}_6\text{H}_5, \text{R}' = \text{CH}_3$	410	52	$\text{R} = 6-\text{CH}_3, \text{R}' = \text{Cl}$	380
29	$\text{R} = \text{CH}_2\text{C}_6\text{H}_5, \text{R}' = \text{OCH}_3$	400	53	$\text{R} = 6-\text{CH}_3, \text{R}' = \text{CH}_3$	380
30	$\text{R} = \text{CH}_2\text{C}_6\text{H}_4\text{Cl}, \text{R}' = \text{CH}_3$	350	54	$\text{R} = 7-\text{CH}_3, \text{R}' = \text{H}$	380
31	$\text{R} = \text{CH}_2\text{C}_6\text{H}_4\text{NO}_2, \text{R}' = \text{CH}_3$	360	55	$\text{R} = 7-\text{CH}_3, \text{R}' = \text{Cl}$	360
32	$\text{R} = \text{CH}_2\text{C}_6\text{H}_4\text{CN}, \text{R}' = \text{CH}_3$	380	56	$\text{R} = 7-\text{OCOCH}_3, \text{R}' = \text{Cl}$	360
33	$\text{R} = \text{COCH}_2\text{CH}_3, \text{R}' = \text{H}$	370	57	$\text{R} = 7-\text{OCOCH}_3, \text{R}' = \text{CH}_3$	370
42	$\text{R} = \text{COCH}_2\text{CH}_3, \text{R}' = \text{Cl}$	390	58	$\text{R} = 5,6-\text{C}_4\text{H}_4, \text{R}' = \text{CH}_3$	370
43	$\text{R} = \text{COCH}_2\text{CH}_2\text{CH}_3, \text{R}' = \text{H}$	380	59	$\text{R} = 7,8-\text{C}_4\text{H}_4, \text{R}' = \text{CH}_3$	370

Table 2

Compound No.	Minimum inhibitory concentration against	
	<i>S.aureus</i>	<i>E.Coli</i>
28	400 μ g/ml	500 μ g/ml
29	400 μ g/ml	500 μ g/ml
31	800 μ g/ml	500 μ g/ml
45	500 μ g/ml	600 μ g/ml
46	500 μ g/ml	NA
47	400 μ g/ml	800 μ g/ml
52	200 μ g/ml	-
54	200 μ g/ml	-
58	200 μ g/ml	-

References:

- 1 Lee K h, Kim S H & Piantadosi C, *pharm. Sci*, 63, 9176,1163.
- 2 Gringuaz A, *Introduction to medical chemistry*(wiley VCH, New york) 1997, pp.305.
- 3 Avetisyan A A & Tokmadzhyan C G, *Chem.Heterocyclic compd*, 23, 1987, 595.
- 4 Klunk W E, Covey D F & Ferrendelli J A, *mol Pharmcol*,22, 1982, 431.
- 5 Harvey S C, *Remington's Pharmaceutical Science*, (Mack publishing company Pennsylvania) 1985, 1189.
- 6 Conquelet J. D., Conquelet J. M., Payard M., Fauran F. & *Ann pharm. Fr*, 36,1978,51.
- 7 Lau C K, Brideu C, Chan C C, Charleson S, Cromlish W A, Ethier D, Gauthier J Y, Gordon R, Guay J, Kargman S, *Bio.Med.Chem Lett*, 15, 1999, 3187.
- 8 Awad W I, Hashem A I & El-Badry K, *Indian J Chem*, 12, 1975, 1139.
- 9 Khattab S A & Hosny M, *Indian H Chem*, 19B, 1980, 1038.
- 10 (a) El-Kousy S M, El-Torgoman A M, El-Basiounyll A A & Hashen A I, *Die Pharmazie* 43, 1988, 80. (b) Filler R, Piasek & Leipoid H A, *Org. Synthesis* , Coll Vol. V. 1973, 80.
- 11 Joshi S D, Usgaonkar R N *Indian J Chem*, 21B,.1982, 399-402.
- 12 a) Ito K, Maruyama J, *Chem.Pharm.Bull.*,1986, 34, 390. b) Robertson A, Sandrock F, Hendry C B, J e) Mashelkar U C and Audi A A, *Journal of Indian Council of Chemists*, 18 (1), 2001, 37. f) Ito K, Kaoru N, *J. Heterocycl. Chem*, 25, 1988, 511.
- 13 Kenny R S and Mashelkar U C, *J. Heterocycl. Chem*, 43, 459, 2006, .
- 14 Lozanova K ,Vasilev G, Kalcheva V, Dokl, *Dulg. Akad Nauk*, 44(9), 1991, 115, *Chem. Abstr*, 116, 1992, 2355169.
- 15 Virinder S Pawar and Nawal K Sharma, *Bio-organic and medicinal chemistry* 11, 2003, 913-929.